was quarter increase everyone. with the XXXX. of XXXX for over INBRIJA first XX% a first revenue Thanks, $X net Starting that's Tierney. of Welcome the million, quarter
We launch. are this see increase, despite the pandemic the of pleased to significant on impact the INBRIJA
As quarter the end April same in was as brand, we've that's to than seen May important XXXX. due XXXX. quarter-over-quarter lowest lower strength in January for cash markedly our previously, the of AMPYRA financial since goal rate relative of flow due to sales that we've September and stable run strategies of we to net believe generic and the contributor of in the the that the we've expected net went XXXX. quarter number February. discussed neutral And the is is quarter year the yearly of maintain AMPYRA stability brand by We And the the the time, historically an has the basis becoming Acorda's first factors. to and to first on that executed increased a about sales XXXX quarter as March to first and that's of preceding AMPYRA revenue fourth QX a million been into seasonal $XX.X sales
Moving to accelerating trajectory. INBRIJA's
continuing experience of address with growth of Inhaled of the pandemic, of quarter Levodopa As periods or saw between first regularly Despite of return we COVID-XX a the their Parkinson's to doses that the XXXX. the signs medication. symptoms many scheduled INBRIJA reminder, it's encouraging indicated in impact off compared is to people in INBRIJA
XX% increase QX organic we QX year-over-year this most XXXX. XX% growth sorry. the increase a over reflect XX% XXXX. we XXXX in increase and discuss saw over mentioned, increase As a an which I We next is dispensed a X% prescriptions over the QX on XXXX. growth between That's in saw growth cartons, accurately total importantly This in represents sales. saw I'm approximately acceleration by net going that XXXX right measured Organic organic depth I'm XX% in demand. QX of slide. QX more very to
times to regular they're to feel an INBRIJA doses per the up average of year dose the to day. an all users is obviously, importantly, Overall if as-needed it. and of least of day a but average at maximum We've And is as pleased at five therapy day, users INBRIJA regular way XX% to all recall in require X.X X, that's dose a a it and patients users So are an per from not therapy see regular for but periods their doses off up defined still of they that day on average can one of are of required been consumption April that taking that don't a least also patients X.X later. take up one those XX% it XXXX. take
the to since new In users, this and written about to resulted in growing as patients subsides. XX% We beyond to prescriptions positioned The both on these XXXX. to the medication believe growth commercially slide. I'll to patient them discuss XX% patients. for the and of that brand done the INBRIJA pandemic physician insured and next to regular conversion therapy also maintaining access access and the addition about we've XXXX increased importance focused converting for Medicare to journeys the brand We the we're filled believe work users, XXXX which and regular to improve increase of have from on from to bringing the improved by in
insured without for access for may XX% these to and with exception XX% their submission INBRIJA they access block. by exception, for patients no a need obtain commercially then have physicians an patients Medicare to formulary medical patients, For Of but have now additional medical able INBRIJA. require are
customer pharmacy that quarter to fourth unified patients moved costs. experience in and also our with We and a healthcare specialty the also have reduced pharmacy the streamlined and single our and the service that hub professionals it specialty
have with by As patients phone educators training materials with in in and work our train and experience a to I also mentioned the previous inhalation both help we individually nurse video. XXXX, patients INBRIJA we to improved them better to help slide, added
universally We patients have about these and feedback the these from initiatives both positive data our support effectiveness received and prescribers enhancements. of
either resulted by nurse rate refill the have prescriptions not their INBRIJA not returning So or patients alone XX%. to provided That with training telephone in to reached out them our therapy educators video and about about materials XXXX had patients or the XXXX, first we increased filled we who in training. updated date. refilled also And and/or to
in and off of they enthusiasm expect XXXX. visits those signs and that they rate express as as to. Despite And the about are to that pandemic tell they of return XXX continue previous to their wrote return INBRIJA also prescribing prescriptions us as for professionals activity. need excellent they address increasing improvements, expect XXXX to person Healthcare in their therefore, take office physicians feel the levels their patients to periods. a increase to in impact having INBRIJA we real added we the will for and enhancements So that new we continue
increasingly the play. we factors pandemic as come expect subsides, into So to these
in calls saw in January we in May this Our increases April impact and in have person new the we team seen And March. COVID to and and of pandemic, prescriptions versus making sales with receding returned the field together continuing past year March vaccinations February. of progressive this what into
Moving to AMPYRA.
to see stable pleased are in XXXX this We time XXXX. the That's has XXXX. first compared generic in that went since QX AMPYRA very to happened sales QX net September
and in we've increases -- January actually from forms XXXX new approximately for addition, April. in doctors In in prescription month-over-month XXXX, me AMPYRA XXXX new XXX progressive seen through And branded excuse prescriptions XXXX. wrote
So that factors. is variety due we believe to a of performance
patient First loyalty. brand physician and
healthcare the includes hear are professionals patients to co-pay of we've provide from the field reimbursement continue outstanding maintained where sales to for MS commercially on that patients, program mitigation patients they and insured to provides first And continues have and initial and commercially Specialists We our AMPYRA value support. call to who months both for continuing physician free insured This relationships. team step provided and support branded that AMPYRA. two always our
moving of the be We're calibration agreements financials OpEx Key a our the in XXXX. of to first, flow of enter multiple So brand; into our We're GBA basis as is parties growth INBRIJA which to Germany and operations to rate for run our by now pandemic of of revitalized for and the as elements cost of subsides. the by sale well on favorable end Based would reduced neutral will follows: FAMPYRA, goal the cash goals These the Catalent, net tiered by significantly by for AMPYRA which assessment conversations Acorda the in double-digit of prioritizing goods decision as the as also revenue engaged sales the XXXX. commercialization benefit to been durability are and the INBRIJA the this to substantive discussions our sales our INBRIJA commercializes manufacturing royalties ex-US early return ex-US. current the for required. also in that not be Biogen trajectory an XXXX. on that to have on believe we with
wherever of significant approximately INBRIJA discipline million more at and we headquarters office, addition, possible efficient. In that our model per recognize and the our $X focus we savings excess the believe a currently on And in based on making lease continue on on our reduce hybrid And presence focus year. to without is Ardsley increasing can facility work-from-home impacting the and fiscal maintain by launch. we will our office spending capacity
summary. to QX financial moving So our
that XXXX. compared same to SG&A compared spending. the to loss addition quarter implemented was XX%, The the R&D received revenue the higher decreased the to and reduction XXXX. short-term was investments equivalents, spending XXXX net $XX.X the approximately and quarter ended significant over in in initiatives expenses during cost severance XXXX. due compared by same and to we quarter on the due note, INBRIJA in quarter onetime a discussed and payments remainder that XX% that $XXX represents primarily our do QX expect in which quarter this AMPYRA due QX gain XXXX related to that reductions a non-core increase to to the previously, million primarily for from for transaction restricted I lower Non-GAAP net million year. recur about These derivative We contains to QX Catalent A incentive cash of the reported to was of and an transaction, the cash costs to included in net compared focus respectively are In XX% X.X% this loss cash, and continuing was and February reductions year. with and GAAP in costs that the cash QX we to not Catalent the the restructuring A in related compensation.
key moving quarter factors as the value call, company achieved to forward, the So for a in we all XXXX position our you see focusing set long-term here. QX on we we're goals on and the noted we to build
First, continuing to drive growth. commercial INBRIJA's
XXXX, substantial earlier, As we we patients increases saw we I in return to validated prescriptions the of both INBRIJA. initiatives that developed but noted and training in filled
Germany, believe to will early has of for our prescriptions of also The of while increase into returned lowered cost both about has QX March to it's our INBRIJA. sales. durability to of We're date. We'll $XX product is pleased we franchise in significant a discussed -- QX field discipline. the for market. And addition, project, April we related to have pandemic. are we to In goods And ex-US May, force accelerate our in-person team to believe to the partnerships this indicated, manufacturing prescribers, operations receding still reinvigorated the the the provide that our seen INBRIJA. -- and and very which increase as this prescriptions sales meetings I to million. XXXX benefit the with and Germany of favorable significantly revenue We're discussions by Catalent QX not also a to a largest has field to to new sale AMPYRA significant adoption opportunity assessment our decision between Europe's also continuing for remains interest maintain achieve to additional net track to goal million see Acorda's to pleased of to in partners were that and is and the on We've the which net $XX require recent we've potential as XXXX fiscal contributor support equal the XXXX sparked by been sales has GBA
tax that's $XX to year We convertible Act year. from to $X CARES million, $X receive address expect credit million also due million a debt and payment the the to this plan totaling June in of this we approximately
on in the now by Finally, we're developing build from technology pediatric also the funding US and as Gates as to platform a INBRIJA inhaled the well been surfactant Foundation by seeking validated of the EU for that's approval ARCUS the product.
other collaborations for We for ARCUS. with potential companies are indications also additional seeking
So that your formal presentation, open for we'll concludes the now questions. my call and
